Disciplines:
  • Dentists
  • Dental Hygienists
  • Dental Assistants
Hours: 2 Contact Hours
Author(s): John F. Kross, DMD, MSc
Peer Reviewer(s):
  • Anders Nattestad, DDS, PhD (Original)
  • Evan B. Rosen, DMD, MPH (Updated 1st Edition)
Item#: L0708
Contents: 1 Course Book (38 pages)
Sign up for the Western Schools 365 Online Membership
Online Access to all our dental CE courses for a full year!

Osteoporosis: Implications for the Oral Healthcare Provider, Updated 1st Edition



Price $19.95
Item # L0708
When available, the Online Course format is included with the hard copy, eBook, or audio book formats!

Release Date: June 29, 2012
Revised Date: June 26, 2015
Expiration Date: June 25, 2018

Both periodontal disease and osteoporosis are serious public-health concerns in the United States. There is evidence that osteoporosis, and the characteristic loss of bone mass, is associated with periodontal disease and tooth loss. To optimize the oral health care of patients with osteoporosis and at risk for the condition, dentists and other members of the dental team should be aware of the clinical (and possibly pathophysiologic) link between these increasingly common conditions. 

This intermediate-level course addresses current concepts regarding links between oral health and osteoporosis, discusses the impact on oral health of pharmacotherapies used in the treatment of osteoporosis, and outlines steps to mitigate the impact on oral health of common drug treatments used to treat osteoporosis. Oral healthcare providers must recognize the oral health implications of common therapeutic options for osteoporosis, especially use of bisphosphonates and antiresorptive medications. In particular, patient exposure to bisphosphonate and antiresorptive drugs has led to increasing reports of osteonecrosis of the jaw. This serious and debilitating condition requires dental practitioners to be alert for signs and symptoms of this syndrome and to take steps to mitigate risk factors. Although the pharmacotherapy used to treat osteoporosis causes concerns for oral health providers, these drugs provide very significant healthcare advantages for the patients, and overall the reduction in osteoporotic fractures alone causes significant savings for the healthcare system. Therefore, care must be taken not to overestimate the oral health ramifications and concerns with these drugs.  


AGD Subject Code: 730

Western Schools designates this activity for 2 continuing education credits.

Course Objectives
  • Describe the etiology and prevalence of osteoporosis.
  • Discuss the putative association between osteoporosis and periodontal disease.
  • Explain the pharmacological treatment of osteoporosis.
  • Describe the oral health implications of medically related jaw necrosis.
  • Identify evidence-based guidelines for the management of bisphosphonate-treated patients.
  • Describe the importance of screening for osteoporosis.
John F. Kross, DMD, MSc, received his doctor of dental medicine degree from Temple University School of Dentistry in Philadelphia. He completed a fellowship at Temple University Hospital in oral oncology and received a hospital appointment to the Department of Dentistry at the Medical Centers of Delaware (now the Christiana Health Care System). His professional training and experience includes practicing general dentistry in Wilmington, Delaware, and New London, Pennsylvania, as well as instructing students in oral pathology at Delaware Technical Community College. He has been composing monographs, creating manuscripts, and contributing to continuing dental education since 1991. Dr. Kross has received numerous academic awards for his work in oral surgery, fixed partial prosthodontics, periodontics, and endodontics. 
Anders Nattestad, DDS, PhD, (Original) is professor and director of oral and maxillofacial surgery at the Arthur A. Dugoni School of Dentistry at the University of the Pacific, San Francisco, CA. He has published more than 45 articles and has presented at more than 100 international meetings all over the world. He served for five years as secretary general of the Association for Dental Education in Europe and was involved in the steering committee of the DentEd project for more than 10 years.

Evan B. Rosen, DMD, MPH, (Updated 1st Edition) is a maxillofacial prosthodontist at the Harvard School of Dental Medicine. Dr. Rosen completed his doctor of dental medicine degree at the University of Florida College of Dentistry and his prosthodontics residency at the Eastman Institute for Oral Health in Rochester, NY. Dr. Rosen continued his professional training by completing a fellowship in maxillofacial prosthetics at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Rosen is actively engaged in research focusing on quality of life outcomes and maintains a faculty practice at the Harvard Dental Center with a focus on treatment of medically complex patients. 

  • Courses must be completed within one (1) year of the date of purchase or by the expiration date indicated above, whichever date comes first.
  • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
  • Through our review processes, Western Schools ensures that the course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support. 
  • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
  • There are no prerequisites for this course.